Neuroendocrine differentiation in the progression of prostate cancer (Q37361501)

19 August 2017

1 reference

title

Neuroendocrine differentiation in the progression of prostate cancer (English)

1 reference

19 August 2017

1 reference

Akira Komiya

1 reference

19 August 2017

Hiroyoshi Suzuki

1 reference

19 August 2017

Takashi Imamoto

1 reference

19 August 2017

Naoto Kamiya

1 reference

19 August 2017

Naoki Nihei

1 reference

19 August 2017

Yukio Naya

1 reference

19 August 2017

Tomohiko Ichikawa

1 reference

19 August 2017

Hideki Fuse

1 reference

19 August 2017

language of work or name

1 reference

1 January 2009

1 reference

International Journal of Urology

19 August 2017

published in

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

37-44

1 reference

Morphologic and molecular prognostic markers in prostate cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Neuroendocrine differentiation in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Neuroendocrine cells in tumour growth of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Neurogenic origin of human prostate endocrine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Neuroendocrine differentiation in human prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Synergistic effects of bombesin and epidermal growth factor on cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Small cell carcinoma of the prostate expressing prostate-specific antigen and showing syndrome of inappropriate secretion of antidiuretic hormone: an autopsy case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02175.X

10.1111/J.1442-2042.2008.02175.X

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference